Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
about
The role of taxanes in triple-negative breast cancer: literature reviewAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsClinical Translation of Nanomedicine.A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastasesA phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer TherapyTargeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.Excellent biochemical response to polychemotherapy with nab-paclitaxel/gemcitabine in an 82-year-old female with metastatic breast cancerSafety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion.Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialThe treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancerNanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.Drug resistance and the role of combination chemotherapy in improving patient outcomes.Nanoparticle Based Combination Treatments for Targeting Multiple Hallmarks of Cancer.Shell-crosslinked knedel-like nanoparticles induce lower immunotoxicity than their non-crosslinked analogs.Novel combinations for the treatment of metastatic breast cancer.Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.Macromolecules as taxane delivery systems.Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.Emerging drugs in metastatic breast cancer: an update.Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research.Safety and efficacy evaluation of albumin-bound paclitaxel.Nanotechnology applications in diagnosis and treatment of metastasis.Pleiotropic Role of Dietary Phytochemicals in Cancer: Emerging Perspectives for Combinational Therapy.Application of albumin-based nanoparticles in the management of cancer.Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.Polymeric micelles for multidrug delivery and combination therapy.Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
P2860
Q26798356-CD857090-8293-4244-B04A-3166ADBB1EFCQ26798674-8D2E49E5-A2AE-40BA-8FA7-489DDDE97145Q30355939-CAB04A08-C36E-400C-B426-E75272EC4416Q33405667-BB8C3B27-7F7D-4B8E-B908-9D925F1B9EB5Q33433212-DA88728E-B2F1-48D3-A10F-034284BFB746Q33859472-C14F0926-6112-4D63-BA91-211EBF8E783DQ33916040-AB9FF23F-BA7C-48F1-894A-D3C1E902C855Q34082844-68610450-EC96-46A6-B0BF-838B023720C3Q34403483-72B329FE-FEE8-4DCD-8D84-A7332B7A4862Q34965672-590588C5-25A3-4266-BF40-C0D7A9FE2189Q35100986-90A45792-DA7E-486F-AFD5-4C44AC1FD830Q35128729-C9C0A10E-9E69-4705-AEC4-7522BCDCB53DQ35507680-731D308A-7E60-4D7B-AC5E-CF48884F81A2Q35872691-84F673BD-98A0-4B80-9BC3-E5CC12EC995FQ36036125-5F9F3C6D-D602-4605-9D9A-E8E96564D655Q36379813-EFF8A64D-5C7E-4CC7-9B1E-E2EB3324C7B3Q36416904-416187D7-F7F3-4EEA-82DB-963FB5FB0345Q36763291-7C776126-8133-4553-8C89-1F2ABCBAFA2DQ36860835-1BB64B41-471B-4778-82B6-77E866AC1CD5Q36901035-8EF2B4BB-AC27-44F0-AD54-0A88FA5E89ADQ36999509-6B8ED493-F00E-4256-A686-58A4A467619BQ37189571-121421C3-FA37-4FE1-B714-4E9AACA27443Q37265121-657DFE25-9673-4053-8094-77FE891507DBQ37307168-A637E0D5-9B38-42F1-B36C-3BE1BD560A92Q37659713-9E80E5AD-3354-4E4A-9AD8-02478301D859Q37725620-5E02C878-A6F3-44BF-90A6-F7D940F1B8B4Q37743510-D67C3AC0-97D9-4360-BC9B-422A7EC08485Q37818236-C2267588-3242-4A18-BE3B-B896B116B64DQ37960507-9BE22EC8-F6AA-43AD-9C49-591C6E540B77Q37961957-FE38D226-3FD5-45E0-8FFB-94D393942195Q37977498-4F115AD5-53DD-49DA-9965-9547C1690BA1Q37981001-2836A739-83A8-451E-904E-C17317402BDDQ38190090-C203A1F0-23F4-4A57-92EF-1DDA9E15C731Q38254086-9CDEBDC9-F86C-4D5E-B6BD-82CC857D206DQ38584742-6925D933-D9F8-4FD0-81C8-74C5DD48D0B3Q38649063-DC1D60A4-E7FD-4633-B1E2-1787ED87CEA5Q39002209-54551EC8-2F6E-4CFD-B7C5-F69BF741A94AQ39243591-D58648E8-750B-4070-B670-44E0C824E652Q39367399-2FC135EF-427F-4DE0-B6C7-C6C318908869Q39380445-493AAF25-AEFD-4765-B9A1-1A72F4AFF81A
P2860
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II trial of weekly nab ( ...... astatic breast cancer (N0531).
@en
Phase II trial of weekly nab
@nl
type
label
Phase II trial of weekly nab ( ...... astatic breast cancer (N0531).
@en
Phase II trial of weekly nab
@nl
prefLabel
Phase II trial of weekly nab ( ...... astatic breast cancer (N0531).
@en
Phase II trial of weekly nab
@nl
P2093
P2860
P356
P1433
P1476
Phase II trial of weekly nab ( ...... astatic breast cancer (N0531).
@en
P2093
B R LaPlant
F M Palmieri
North Central Cancer Treatment Group
P2860
P304
P356
10.1093/ANNONC/MDN661
P577
2008-12-15T00:00:00Z